AlphAIAlphAI — Financial news for AI agents
stocktitan.netSEP 21 min read$TENX

Investment funds tied to Tenax (TENX) 10% owner just bought more stock

ADAR1 Capital Management, LLC, a 10% owner of Tenax Therapeutics (TENX), reported buying 770,333 shares of common stock from August 31 to September 2, 2026, at an average price of $1.79 per share, ranging from $1.77 to $1.80. The purchases were made indirectly through private investment funds managed by ADAR1.

Original reporting
stocktitan.net
Published Sep 2, 2026, 9:53 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 3, 2026, 5:24 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefFinancial news
Primary signal
$TENX
Bullish
medium confidence
Mentioned
$TENX
Relevance
4/10
AlphAI data visualization · based on stocktitan.net
Decision brief

The 30-second read

$TENXBullishLow
01

Why it matters

The disclosed insider buying may provide a modest catalyst for short‑term price appreciation.

02

Market read

While the purchase is modest, it adds a positive data point for TENX investors.

03

What to watch

The total share float and recent price performance may dilute the impact of a $1.4M buy.

Relevance 4/10Novelty 4/10Timing: recent (reported Aug 31‑Sep 2, 2026)

Background

Form 4 filing reveals private funds linked to ADAR1 Capital increased their stake in TENX.

Company-level read

Ticker impact

$TENXBullishMedium confidence
Context

ADAR1 Capital funds, a 10% owner, bought 770,333 TENX shares at $1.77‑$1.80 each (≈$1.4M) between Aug 31‑Sep 2, 2026.

Expected impact

Modest upward pressure; potential 2‑3% rally if market perceives the purchase as a signal.

Evidence & confidence

The purchase size is modest relative to market cap, but the buyer is a known 10% owner, indicating possible support for the stock.

Market effects

Sector

Signals potential confidence in biotech/therapeutics sector but limited broader impact.

Regional

US biotech market may see slight uptick in sentiment for similar micro‑caps.

Global

Minimal; confined to TENX and its immediate investor base.

Counterpoint

What could challenge this read

Insider purchase could be a routine portfolio rebalancing, not a strong bullish indicator.

Key entities

  • company
    Tenax Therapeutics, Inc.

    Biopharma company listed on Nasdaq under ticker TENX.

  • investment_fund
    ADAR1 Capital Management, LLC

    Private investment manager and 10% owner of TENX.

Read at source← All news

Related articles

SEP 4
$TENXMedAI 8/10

Tenax (TENX) Found a 26.3-Meter Benefit in a Prespecified Subgroup After LEVEL Missed Its Primary Endpoint. Is Another Phase 3 Trial Viable?

Tenax Therapeutics (TENX) reported that its Phase 3 LEVEL trial for TNX-103 missed primary endpoints but showed a 26.3-meter benefit in a prespecified subgroup of patients with severe baseline impairment. The company has $118.0 million in cash and plans to seek regulatory input for an enriched LEVEL-2 trial. Safety data was comparable between treatment and placebo groups.

insidermonkey.com2 min
AUG 31
$TENXHighAI 9/10

Why is Tenax Therapeutics stock volatile today?

Tenax Therapeutics (TENX) stock rose 3.8% in pre-market trading after presenting additional Phase 3 trial data at the European Society of Cardiology Congress. The data showed favorable treatment effects for TNX-103 in patients with severe pulmonary hypertension due to heart failure. Several Wall Street firms initiated coverage with Buy ratings and price targets of $35-$40. The company has $118 million in cash, providing a runway through Q2 2028.

investing.com2 min
AUG 29
$TENXMedAI 8/10

Tenax Therapeutics Presents Additional Phase 3 LEVEL Data Showing TNX-103 Benefits in PH-HFpEF Patients With Lower Baseline Walk Distance

Tenax Therapeutics (TENX) presented additional Phase 3 LEVEL trial data showing TNX-103 improved 6MWD, NT-proBNP, and RVSP in PH-HFpEF patients with lower baseline walk distance. The company plans to enrich the LEVEL-2 population based on these results. TNX-103 showed a 26.3m 6MWD improvement, 47% NT-proBNP reduction, and 4.9 mmHg RVSP reduction vs. placebo in this subgroup.

quiverquant.com3 min
AUG 29
$TENXMedAI 8/10

Tenax Therapeutics Announces Presentation of Phase 3 LEVEL Results in Late-Breaking Scientific Sessions at ESC Congress 2026

Tenax Therapeutics presented Phase 3 LEVEL trial results at ESC Congress 2026. TNX-103 showed significant improvements in patients with PH-HFpEF and baseline 6MWD below 333 meters, including a 26.3m walk distance improvement, 47% NT-proBNP reduction, and 4.9 mmHg RVSP reduction. The company plans to enrich the population for the next study.

finance.yahoo.com2 min
AUG 11
$TENXMed

A Wild Day In Biotech

Biotech stocks moved sharply after clinical and guidance updates. Tenax Therapeutics (TENX) fell nearly 90% after its Phase 3 LEVEL trial of TNX-103 missed primary and key secondary endpoints. AbCellera Biologics (ABCL) rose on Phase 2 results for ABCL635 in menopausal vasomotor symptoms. 10x Genomics (TXG) gained after raising full-year revenue guidance and citing strong early Atera demand.

zerohedge.com6 min
AUG 11
$TENXHighAI 9/10

Tenax Thera tanks on Phase III trial miss for TNX-103 in PH-HFpEF

Tenax Therapeutics (Nasdaq: TENX) shares fell about 90% to $1.38 after it reported Phase III LEVEL trial top-line results for TNX-103 (oral levosimendan) in PH-HFpEF. The trial did not meet the primary endpoint of improving 6-minute walk distance versus placebo, nor a key secondary endpoint on Kansas City Cardiomyopathy Questionnaire symptom score, according to the company.

thepharmaletter.com2 min